AML
Conditions
Interventions
Venetoclax combined with medium-dose cytarabine :None
Sponsors
Qilu Hospital of Shandong University
Eligibility
Sex/Gender
All
Age
18 Years to 59 Years
Inclusion criteria
Inclusion criteria: 1: Age 18-59, male and female. 2: Adult patients with AML (non-APL) who can tolerate intense chemotherapy and who have achieved CR/CRi after induction chemotherapy but MRD-positive are treated with consolidation therapy using Venetoclax in combination with medium-dose cytarabine. 3: Patients with concomitant FLT3 mutations can be treated with the addition of targeted agents. 4: Subjects voluntarily sign an informed consent form.
Exclusion criteria
Exclusion criteria: 1: Patients have a history of myeloproliferative neoplasms (MPN), including myelofibrosis, essential thrombocythemia, true erythrocytosis, chronic myelogenous leukemia (CML), and AML with BCR-ABL1 translocation or acute promyelocytic leukemia (APL). 2: Secondary AML with a history of MDS 3: Central nervous system infiltration with active leukemia 4: Clinically uncontrolled active infection and organ hemorrhage 5: Combination of severe abnormalities of vital organ function and other malignant tumors 6: Mental disorders that would prevent research participation 7: Patients who are pregnant or breastfeeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| MRD conversion rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| DOR, EFS, OS;TRM; | — |
Countries
China
Contacts
Public ContactChunyan Chen
Qilu Hospital of Shandong University
Outcome results
None listed